NEW YORK (GenomeWeb News) — Illumina and the Mayo Clinic today said they plan to co-develop molecular diagnostics for certain undisclosed diseases, Illumina said today.
Under the agreement, Illumina will provide its VeraCode technology and its know-how on the BeadArray platform to Mayo Medical Laboratories, which have had the technology since January 2005.
Mayo Labs will use the systems to discover and validate biomarkers offering the “potential for both parties to implement important new clinical tests,” Illumina said.
Illumina will then make and market tests worldwide on its BeadArray and upcoming BeadXpress reader using biomarkers or other IP Mayo develops, the company said.
“Expanding our relationship with Mayo Clinic … represents an important step in the revolution of our diagnostics strategy,” said Jorge Velarde, Illumina’s senior director of business development.
Financial terms of the agreement were not released.